Introduction
Cervical cancer is a common gynecological malignant tumor and is the
fourth most prevalent cancer in women.[1]Statistically, approximately 570,000 cases of cervical cancer and
311,000 related deaths were reported in 2018[2].
Neuroendocrine carcinoma of the cervix (NECC) is a rare type of cervix
cancer. It has a bad prognosis and acts more aggressively than other
prevalent types, despite constituting only 1–1.5% of all cervical
cancer cases.[3] The five-year survival rate of
patients with NECC is only 0–30%.[4]
Research on NECC is scarce, particularly in terms of prognosis owing to
its low prevalence. Previous studies indicated that the FIGO stages may
serve to determine the prognosis of the survival and the adjuvant
chemotherapy following radical surgery was the preferred treatment
option for Korean women with early-stage NECC.[5]In another study, surgery and lymphadenectomy appeared to have a
substantial impact on the survival of patients with NECC when compared
to chemotherapy and radiotherapy.[6] However, the
National Comprehensive Cancer Network (NCCN) recommends etoposide plus
cisplatin as the optimal treatment option for cervical
cancer.[7] Furthermore, paclitaxel plus cisplatin
may be a more efficient treatment modality than etoposide plus
cisplatin.[8] No consensus has been established on
the prognostic factors and treatment of NECC, and to date, scarcely
study has shown the relationship between pathological results and
prognosis. We conducted a multi-center retrospective study to analyze
the relationship between pathological results and survival outcomes and
explore the prognostic factors and research for better treatment of the
disease by analyzing the clinicopathological data and therapeutic
strategies of patients with NECC.